# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.
The Transaction is structured as an equity sale. The Transaction terms also include the opportunity for STERIS to receive an ad...
Stephens & Co. analyst Jacob Johnson reiterates Steris (NYSE:STE) with a Overweight and maintains $250 price target.
JMP Securities analyst David Turkaly reiterates Steris (NYSE:STE) with a Market Outperform and maintains $265 price target.
Adjusted earnings per diluted share revised due primarily to a shift in operating income mix from AST to Healthcare.